Akero Therapeutics is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious metabolic diseases. The company's initial focus is on nonalcoholic steatohepatitis ("NASH"), a disease without any approved therapies. NASH is a severe form of nonalcoholic fatty liver disease ("NAFLD"), characterized by inflammation and fibrosis in the liver that can progress to cirrhosis, failure, cancer of the liver, and death. The company is developing AKR-001, an analog of fibroblast growth factor 21 ("FGF21"), for NASH and plan to initiate a Phase 2a clinical trial for AKR-001 in NASH patients with fibrosis in the middle of 2019.
Apellis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on treating disease through the inhibition of the complement system, which is a component of the immune system, at the level of C3, the central protein in the complement cascade. The company's clinical program targets C3 with Phase 3 clinical trials of its main product candidate, APL-2, in multiple indications. APL-2 has the potential to be a treatment that address the limitations of existing treatment options or provide a treatment option. The company is also conducting a Phase 2 trial of APL-2 in glomerular diseases, including C3 glomerulopathy, IgA nephropathy, primary membranous nephropathy and lupus nephritis.
Caledonia Mining Corporation is engaged in the acquisition, exploration and development of mineral properties for the exploitation of base and precious metals focused on Southern Africa. Co.'s primary asset is a 49% interest in the Blanket Mine in Zimbabwe which produced over 50,351 ounces of gold in 2016. Its segments include Corporate, Zimbabwe, and South Africa. The Corporate segment includes administrative functions within the group. The Zimbabwe segment comprise Caledonia Holdings Zimbabwe Ltd. and subsidiaries. The South Africa segment comprises a gold mine, that is on care and maintenance, as well as sales made by Caledonia Mining South Africa Proprietary Limited to the Blanket Mine.
Cross Country Healthcare provides healthcare staffing, recruiting and workforce solutions. The company's business consists of three business segments: Nurse and Allied Staffing, which provides staffing, recruiting, and workforce solutions including temporary and permanent placement of travel and local branch-based nurse and allied personnel; Physician Staffing, which provides physicians, certified registered nurse anesthetists, nurse practitioners and physician assistants under its Medical Doctor Associates brand; and Other Human Capital Management Services, which is comprised of retained and contingent search services for physicians, healthcare executives, and other healthcare personnel.
Harrow Health focuses on the development, production and sale of medications. The company mainly focuses on its ImprimisRx business, which is an ophthalmology pharmaceutical compounding business, and Park Compounding, Inc., which is a pharmacy focused primarily on health and wellness related, customizable pharmaceutical compounding. The company's other subsidiaries include: Eton Pharmaceuticals, Inc., a pharmaceutical company focused on developing and commercializing products utilizing the U.S. Food and Drug Administration 505(b)(2) regulatory pathway; and Surface Pharmaceuticals, Inc., a pharmaceutical company focused on development and commercialization of therapeutics for ocular surface diseases.
IVERIC bio is a biopharmaceutical company focused on the discovery and development of treatment options for retinal diseases with unmet medical needs. The company is developing both therapeutics for age-related retinal diseases and gene therapy product candidates for orphan inherited retinal diseases. The company's product candidate Zimura, a complement inhibitor, is a chemically-synthesized, pegylated RNA aptamer. The company's clinical trials for Zimura include: OPH2003, for patients with geographic atrophy secondary to dry age-related macular degeneration; and OPH2005, for the treatment of Stargardt disease.
MGP Ingredients is a producer and supplier of distilled spirits and specialty wheat protein and starch food ingredients. The company has two reportable segments: distillery products and ingredient solutions. The distillery products segment processes corn and other grains (including rye, barley, wheat, barley malt, and milo) into food grade alcohol and distillery co-products, such as distillers feed (called dried distillers grain in the industry), fuel grade alcohol, and corn oil. The company also provides warehouse services. The ingredient solutions segment consists primarily of specialty wheat starches, specialty wheat proteins, commodity wheat starches, and commodity wheat proteins.
Murphy Oil is a holding company. Through its subsidiaries, the company is an oil and natural gas exploration and production company. The company explores for and produces crude oil, natural gas and natural gas liquids worldwide. The company's principal exploration and production activities are conducted in United States by wholly owned Murphy Exploration & Production Company - USA and its subsidiaries, in Canada by wholly-owned Murphy Oil Company Ltd. and its subsidiaries, and in Australia, Brazil, Brunei, Mexico and Vietnam by wholly-owned Murphy Exploration & Production Company - International and its subsidiaries. The company's hydrocarbon production is in United States, Canada and Brunei.
Northern Technologies International develops and markets proprietary products and services either directly or via a network of subsidiaries, joint ventures, independent distributors, and agents. The company's primary business is corrosion prevention marketed mainly under the ZERUST? brand. The company sells its proprietary ZERUST? products and services to the automotive, electronics, electrical, mechanical, military and retail consumer markets, and the oil and gas industry. The company also markets and sells a portfolio of bio-based and certified compostable (fully biodegradable) polymer resin compounds and finished products under the Natur-Tec? brand.
Ranger Energy Services is a holding company. Through its subsidiaries, the company provides onshore well service rigs, wireline completion services and additional complementary services. The company's segments include: High Specification Rigs, which provides well and complementary equipment and services to facilitate operations throughout the lifecycle of a well; Completion and Other Services, which provides wireline completion services and other ancillary services; and Processing Solutions, which engages in the rental, installation, commissioning, start-up, operation and maintenance of Mechanical Refrigeration Units, Nitrogen Gas Liquid (NGL) stabilizer units, NGL storage units and related equipment.
Revance Therapeutics is a clinical-stage biotechnology company focused on the development, manufacturing and commercialization of neuromodulators for multiple aesthetic and therapeutic indications. The company focuses on developing daxibotulinumtoxinA, its purified botulinum toxin Type A, for a spectrum of aesthetic and therapeutic indications, including facial wrinkles, muscle disorders, and chronic migraine. The company's main drug candidate is DaxibotulinumtoxinA for Injection. The company also is developing a topically applied neuromodulator for aesthetic and therapeutic indications, DaxibotulinumtoxinA Topical, and have a collaboration and license agreement to develop and commercialize a biosimilar to BOTOX?.
Spok Holdings provides a suite of unified clinical communication and collaboration solutions that include call center operations, clinical alerting and notifications, one-way and two-way wireless messaging services, mobile communications and public safety solutions. The company also develops, sells and supports enterprise-wide systems for hospitals and other organizations needing to automate, centralize and standardize mission clinical communications. These solutions are used for contact centers, clinical alerting and notification, mobile communications and messaging and for public safety notifications.
Vermilion Research delivers timely, actionable, and unique research inputs to professional investors. Our research strategists highlight securities which we believe are at major inflection points, based on our various proprietary technical indicators, and offer asymmetric risk/return profiles. We believe our research methodology, which is not limited by industry sector or market capitalization, enables us to deliver superior investment recommendations.
Our process begins by organizing all actively traded stocks into coherent sectors, then into logical industry groups. We then apply our proprietary relative strength tools to identify developing price trends. Once attractive trends are identified within a selected sectors or groups, we screen for individual stocks which we believe offer the best risk/reward profile. Vermilion offers U.S. and global equity market research products. Vermilion’s research team, which has received numerous awards and accolades, has a combined 70 year of experience in the analysis of investment securities.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.